Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

BOLD

Boundless Bio Inc.

May 17 • 10:57AM ET

9.69

Dollar change -0.27
Percentage change -2.66	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VTWO VTWG VTWV VTHR

Index	-	P/E	-	EPS (ttm)	-	Insider Own	46.38%	Shs Outstand	22.24M	Perf Week	12.86%
Market Cap	215.71M	Forward P/E	-	EPS next Y	-4.59	Insider Trans	9.70%	Shs Float	11.93M	Perf Month	-14.20%
Income	-	PEG	-	EPS next Q	-0.80	Inst Own	53.66%	Short Float	7.12%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	90.18%	Inst Trans	-	Short Ratio	4.16	Perf Half Y	-
Book/sh	-111.82	P/B	-	EPS next Y	-15.16%	ROA	-	Short Interest	0.85M	Perf Year	-
Cash/sh	4.71	P/C	2.06	EPS next 5Y	-	ROE	-	52W Range	8.51 - 15.24	Perf YTD	-31.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-36.38%	Beta	-
Dividend TTM	-	Quick Ratio	10.54	Sales past 5Y	0.00%	Gross Margin	-	52W Low	13.92%	ATR (14)	1.01
Dividend Ex-Date	-	Current Ratio	10.54	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	41.43	Volatility	10.85% 11.73%
Employees	72	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	23.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-2207.48%	Payout	-	Rel Volume	0.20	Prev Close	9.96
Sales Surprise	-	EPS Surprise	-1817.19%	Sales Q/Q	-	Earnings	May 13 BMO	Avg Volume	204.39K	Price	9.69
SMA20	-3.51%	SMA50	-11.91%	SMA200	-11.91%	Trades		Volume	10,589	Change	-2.66%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	Piper Sandler	Overweight	$20
Apr-22-24	Initiated	Leerink Partners	Outperform	$25
Apr-22-24	Initiated	Guggenheim	Buy	$24

May-13-24 02:53PM	BOLD Stock Earnings: Boundless Bio Reported Results for Q1 2024 (InvestorPlace) +10.83%
07:00AM	Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights (Business Wire)
May-06-24 08:00AM	Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 (Business Wire)
May-01-24 10:05AM	Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050 (PR Newswire)
Apr-14-24 11:37AM	Insiders are Amassing These 10 Stocks in April (Insider Monkey)
08:00AM	Loading…
Apr-11-24 08:00AM	Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications (Business Wire)
Apr-08-24 08:00AM	Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 (Business Wire) -5.75%
Mar-27-24 06:55PM	Boundless Bio Announces Pricing of Initial Public Offering (Business Wire)

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Apr 02 '24	Buy	16.00	312,500	5,000,000	1,884,787	Apr 04 04:15 PM
ARCH Venture Fund IX, L.P.	10% Owner	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM
CRANDELL KEITH	10% Owner	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM
Burow Kristina	Director	Apr 02 '24	Buy	16.00	200,000	3,200,000	1,181,766	Apr 04 04:30 PM

Open in Screener

NMRA

Neumora Therapeutics Inc.

May 17 • 10:57AM ET

9.56

Dollar change -0.07
Percentage change -0.73	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: IWM VXF SBIO SCHA IWN IWO VTWO ONEQ BBSC SMLF

Index	RUT	P/E	-	EPS (ttm)	-1.62	Insider Own	65.96%	Shs Outstand	158.83M	Perf Week	4.03%
Market Cap	1.53B	Forward P/E	-	EPS next Y	-1.58	Insider Trans	0.00%	Shs Float	54.30M	Perf Month	-9.38%
Income	-254.02M	PEG	-	EPS next Q	-0.37	Inst Own	20.48%	Short Float	12.12%	Perf Quarter	-51.62%
Sales	0.00M	P/S	-	EPS this Y	59.27%	Inst Trans	-	Short Ratio	10.46	Perf Half Y	-20.40%
Book/sh	2.66	P/B	3.59	EPS next Y	-6.57%	ROA	-60.32%	Short Interest	6.58M	Perf Year	-
Cash/sh	2.65	P/C	3.61	EPS next 5Y	-	ROE	-64.28%	52W Range	8.82 - 21.00	Perf YTD	-43.93%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-59.70%	52W High	-54.48%	Beta	-
Dividend TTM	-	Quick Ratio	17.99	Sales past 5Y	0.00%	Gross Margin	-	52W Low	8.39%	ATR (14)	0.69
Dividend Ex-Date	-	Current Ratio	17.99	EPS Y/Y TTM	-99.66%	Oper. Margin	0.00%	RSI (14)	40.32	Volatility	6.39% 6.80%
Employees	124	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	24.51
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-43.81%	Payout	-	Rel Volume	0.25	Prev Close	9.63
Sales Surprise	-	EPS Surprise	0.58%	Sales Q/Q	-	Earnings	May 07 BMO	Avg Volume	629.01K	Price	9.56
SMA20	0.53%	SMA50	-21.91%	SMA200	-28.85%	Trades		Volume	41,528	Change	-0.73%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-23	Initiated	Deutsche Bank	Hold	$13
Oct-10-23	Initiated	William Blair	Outperform	$26
Oct-10-23	Initiated	Stifel	Buy	$26
Oct-10-23	Initiated	RBC Capital Mkts	Outperform	$24
Oct-10-23	Initiated	JP Morgan	Overweight	$21
Oct-10-23	Initiated	Guggenheim	Buy	$22
Oct-10-23	Initiated	BofA Securities	Buy	$18

May-14-24 08:52AM	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression (MT Newswires) +6.92%
07:00AM	Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression (GlobeNewswire)
May-07-24 01:54PM	NMRA Stock Earnings: Neumora Therapeutics Meets EPS for Q1 2024 (InvestorPlace)
10:20AM	Neumora Therapeutics Shares Fall as Q1 Loss Narrows (MT Newswires)
07:00AM	Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
May-06-24 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in May (GlobeNewswire)
Apr-16-24 11:28AM	Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug (Zacks)
Apr-15-24 04:20PM	Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug (Investor's Business Daily) -17.48%
12:17PM	Why Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday? (Benzinga)
08:45AM	Why Is Neumora Therapeutics (NMRA) Stock Down 25% Today? (InvestorPlace)
07:47AM	Neumoras schizophrenia drug hit with clinical hold (BioPharma Dive)
06:36AM	U.S. FDA places clinical hold on Neumora's schizophrenia drug study (Reuters)
06:30AM	Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study (GlobeNewswire)
Mar-13-24 07:00AM	Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days (GlobeNewswire) -14.64%
Mar-07-24 02:52PM	NMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
07:00AM	Loading…
07:00AM	Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jan-22-24 07:00AM	Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer (GlobeNewswire) +9.89%
Jan-10-24 08:32AM	Why Neumora Therapeutics (NMRA) Stock Might be a Great Pick (Zacks)
Jan-02-24 07:00AM	Neumora Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-17-23 12:35PM	7 Stocks with Strong Insider Buying: December 2023 (InvestorPlace)
Dec-12-23 07:00AM	Neumora Therapeutics Appoints Jason Duncan as Chief Legal Officer (GlobeNewswire)
Nov-27-23 07:00AM	Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study (GlobeNewswire)
Nov-01-23 07:00AM	Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-30-23 07:00AM	Neumora Therapeutics to Participate in Upcoming Conferences in November (GlobeNewswire) -6.00%
Oct-10-23 07:00AM	Neumora Therapeutics Announces Appointment of Robert Lenz, M.D., Ph.D., as Executive Vice President, Head of Research and Development (GlobeNewswire) -6.45%
Sep-28-23 07:54PM	Ticking Time Bombs: 3 New Stocks to Dump Before the Damage Is Done (IPO) (InvestorPlace) +11.84%
Sep-27-23 06:50PM	Tracking 2023's Largest IPOs: Instacart, Arm, Birkenstock and More (Updated November) (Observer)
Sep-18-23 12:35PM	UPDATE 3-Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation (Reuters) -8.92%
Sep-14-23 08:49PM	Neumora Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burow Kristina	Director	Nov 14 '23	Buy	11.98	3,357	40,217	4,131,207	Nov 15 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 14 '23	Buy	11.98	3,357	40,217	4,131,207	Nov 15 06:54 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850	Nov 15 06:54 PM
Burow Kristina	Director	Nov 13 '23	Buy	11.75	31,653	371,923	4,127,850	Nov 15 06:55 PM
Burow Kristina	Director	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197	Nov 13 07:01 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 10 '23	Buy	11.49	17,275	198,481	4,096,197	Nov 13 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922	Nov 13 07:00 PM
Burow Kristina	Director	Nov 09 '23	Buy	10.53	31,079	327,262	4,078,922	Nov 13 07:01 PM
Burow Kristina	Director	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843	Nov 13 07:01 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 08 '23	Buy	11.03	92,251	1,017,821	4,047,843	Nov 13 07:00 PM
Burow Kristina	Director	Nov 07 '23	Buy	11.50	30,192	347,208	3,955,592	Nov 07 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 07 '23	Buy	11.50	30,192	347,208	3,955,592	Nov 07 06:59 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 06 '23	Buy	11.55	43,082	497,597	3,925,400	Nov 07 06:59 PM
Burow Kristina	Director	Nov 06 '23	Buy	11.55	43,082	497,597	3,925,400	Nov 07 07:00 PM
Burow Kristina	Director	Nov 03 '23	Buy	11.38	22,420	255,140	3,882,318	Nov 07 07:00 PM
ARCH Venture Partners XII, LLC	10% Owner	Nov 03 '23	Buy	11.38	22,420	255,140	3,882,318	Nov 07 06:59 PM
Burow Kristina	Director	Sep 29 '23	Buy	13.98	34,560	483,149	3,859,898	Sep 29 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 29 '23	Buy	13.98	34,560	483,149	3,859,898	Sep 29 06:53 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 28 '23	Buy	13.44	41,951	563,699	3,825,338	Sep 29 06:53 PM
Burow Kristina	Director	Sep 28 '23	Buy	13.44	41,951	563,699	3,825,338	Sep 29 06:55 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 27 '23	Buy	12.31	24,504	301,644	3,783,387	Sep 27 08:18 PM
Burow Kristina	Director	Sep 27 '23	Buy	12.31	24,504	301,644	3,783,387	Sep 27 08:19 PM
Burow Kristina	Director	Sep 26 '23	Buy	11.73	34,000	398,820	3,758,883	Sep 27 08:19 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 26 '23	Buy	11.73	34,000	398,820	3,758,883	Sep 27 08:18 PM
Burow Kristina	Director	Sep 25 '23	Buy	11.22	60,740	681,464	3,724,883	Sep 25 09:37 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 25 '23	Buy	11.22	60,740	681,464	3,724,883	Sep 25 09:38 PM
ARCH Venture Partners XII, LLC	10% Owner	Sep 22 '23	Buy	11.14	40,000	445,600	3,664,143	Sep 25 09:38 PM
Burow Kristina	Director	Sep 22 '23	Buy	11.14	40,000	445,600	3,664,143	Sep 25 09:37 PM
AMGEN INC	10% Owner	Sep 19 '23	Buy	17.00	1,764,705	29,999,985	35,368,653	Sep 19 07:52 PM
Burow Kristina	Director	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:23 AM
ARCH Venture Partners X, LLC	10% Owner	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:16 AM
ARCH Venture Partners X, LLC	10% Owner	Sep 19 '23	Buy	17.00	1,500,000	25,500,000	3,624,143	Sep 20 06:15 AM
Gosebruch Henry O	President & CEO	Sep 19 '23	Buy	12.62	15,000	189,370	15,000	Sep 19 09:47 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

BOLD

Boundless Bio Inc.

NMRA

Neumora Therapeutics Inc.

Upgrade your FINVIZ experience